Medigus Ltd. American Depositary Share Stock Price, News & Analysis

Medigus Ltd. (Nasdaq: MDGS) announced a successful procedure using its FDA-approved MUSE™ system, performed by Golden Grand, which was broadcast live on Chinese TV. This milestone in their licensing agreement will result in a total payment of $2.4 million to Medigus, with $600,000 received for this specific procedure. The MUSE™ system, a device for incisionless treatment of gastroesophageal reflux disease (GERD), marks a step in Medigus' strategy to expand its licensing agreements globally.

Medigus Ltd. (MDGS) announced the appointment of Arik Priel as Chief Software Architect and Roee Peled as Vice President of Business Development for ScoutCam Inc., a leader in Industry 4.0 visualization solutions. Priel has over 20 years of experience in R&D and engineering, while Peled specializes in IoT and B2B sales processes. These appointments are aimed at enhancing ScoutCam's capabilities in Predictive Maintenance and expanding its market reach. CEO Yovav Sameah emphasized the need for leadership to drive innovation and adapt the business model towards recurring revenue.

Medigus Ltd. (Nasdaq: MDGS) announced promising pre-clinical data from its affiliate Polyrizon regarding its Capture and Contain (C&C™) hydrogel technology. The data suggests that the lead product candidate, PL-14, has potential to prevent allergic reactions caused by house dust mites and Timothy grass pollen allergens, potentially reducing inflammatory responses. The first efficacy results are anticipated within the next 12 months. Medigus continues to focus on advanced medical solutions and innovative technologies.

Medigus Ltd. (Nasdaq: MDGS) has entered a non-binding MOU with Safee to establish a joint venture focused on the buying and selling of non-fungible tokens (NFTs) and digital assets. Medigus plans to provide up to $5 million in funding for NFT acquisitions and will control the JV's management, appointing three of the four board members. In return for consulting services, Safee may purchase 200,000 shares of Medigus stock at $10 each over the next three years. This partnership aims to broaden the NFT market reach.

Medigus Ltd. (Nasdaq: MDGS) announced that Polyrizon Ltd. has partnered with a Contract Research Organization (CRO) to facilitate the U.S. FDA submission for its nasal gel products designed to combat viruses such as COVID-19 and influenza. The CRO will assist in creating a readiness plan for these preventative products. Polyrizon's innovative hydrogel platform has shown promising results in pre-clinical studies, indicating its ability to capture and contain specific viruses. Additionally, a patent application has been submitted for these products, enhancing their market potential.

Medigus Ltd. (Nasdaq: MDGS) announced a memorandum of understanding with Safee Cyber Technologies to enhance digital asset monetization. This partnership allows Eventer, Medigus' affiliate, to enable customers to create and sell NFTs via Safee’s platform. The collaboration aims to provide a recurring revenue model for creators while promoting NFT accessibility to a broader audience. As part of the agreement, both parties will exchange stakes based on their respective valuations of $30 million for Eventer and $35 million for Safee.

Medigus Ltd. (Nasdaq: MDGS) announced that its affiliate Gix Internet acquired 70% of Cortex Group for approximately $11 million, based on a pre-money valuation of $15.6 million. Cortex reported impressive financial growth, with revenues of about $13.5 million for H1 2021, a 53% increase year-over-year, and an operating profit of $1.3 million, up 121%. Q3 2021 also showed strong performance, with revenues of $12.5 million, a 92% increase. This acquisition is expected to significantly enhance Gix's financial results for 2021.

Medigus Ltd. (Nasdaq: MDGS) has announced a strategic investment of $400,000 in Safee, a Non-Fungible Token (NFT) technology firm. This investment will secure approximately 2.5% ownership in Safee. The company's platform aims to simplify NFT ownership for creators and consumers, fostering engagement and monetization in the digital marketplace. Medigus focuses on expanding NFT technology among mass-market audiences, enabling users to create, own, and trade digital assets securely. This collaboration aligns with Medigus’ innovative growth strategy in technology solutions.